Moving Beyond Intent: Building More Diverse Clinical Trials

Published: 23 July 2026

Author(s): Shambhavi Chidambaram

The importance of diversity in clinical trials is no longer a matter of debate. Across the pharmaceutical industry, sponsors, regulators, researchers, and patient advocates increasingly recognise that clinical trial populations should better reflect the communities that will ultimately use approved therapies. Representative enrolment is essential for understanding how treatments perform across different populations and for ensuring that new therapies are safe and effective.

Yet, despite widespread commitment to improving diversity, enrolment challenges persist.